We use cookies for a better user experience. Read our Privacy Policy

I Agree

Non-invasive Prenatal Testing Market

Non-invasive Prenatal Testing Market (Test Type: Materni21, Harmony, Panorama, Verifi, NIFTY, and Others; and Technology: NGS, WGS, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Non-invasive Prenatal Testing Market Outlook 2031

  • The global market was valued at US$ 2.1 Bn in 2022
  • The global market is projected to advance at a CAGR of 14.8% from 2022 to 2031
  • The market is anticipated to reach more than US$ 8.4 Bn by the end of 2031

Analysts’ Viewpoint on Market Scenario

Demand for non-invasive prenatal testing (NIPT) is increasing in several countries owing to the rise in number of doctors preferring advanced non-invasive DNA test for high-risk pregnancies, desire to delay pregnancy, and growth in pregnancy-related issues in the second or third trimester. The global market (NIPT) market is highly saturated, with the presence of a large number of players.

Companies are entering into partnerships and collaborations to maintain a stable position in the market. Improvements and advancements in existing products such as prenatal paternity testing and non-invasive prenatal paternity testing are driving the global market. Furthermore, countries such as the Netherlands are implementing policies to fully reimburse NIPT in the second trimester, which is resulting in higher adoption of these tests. Additionally, other countries such as Germany plan to reimburse non-invasive prenatal tests for chromosomal disorders such as Down’s syndrome.

Non-invasive Prenatal Testing Market

Non-invasive Prenatal Testing Market Introduction

Non-invasive prenatal testing (NIPT) is a novel genetic screening method based on the analysis of cell-free fetal DNA in the maternal plasma. NIPT screens for trisomy 21 (Down syndrome) as well as two other less common chromosome abnormalities: trisomy 13 and trisomy 18. Several companies are striving to create advanced screening methods that are sensitive and accurate in the early diagnosis of genetic abnormalities in infants.

Next-generation sequencing (NGS) is a commonly used technology for the identification of trisomy, micro-deletions, and aneuploidies in chromosomes. NGS-based noninvasive prenatal tests are different from other techniques, as they can be performed as early as 10 weeks of pregnancy. Additionally, other noninvasive prenatal tests offer about 96% accuracy, while NGS-based tests are more than 99% accurate.

Request a sample to get extensive insights into the Non-invasive Prenatal Testing Market

Better Accuracy and Short Duration of Procedure Augmenting Global Non-invasive Prenatal Testing Market Size

The high incidence rate of babies born with Down’s syndrome and Turner’s syndrome across the globe is likely to drive the demand for non-invasive prenatal testing, primarily due to the high level of accuracy and safety offered over conventional screening and invasive diagnostic methods. The advantages of non-invasive prenatal tests, such as non-invasive nature, better accuracy, and short duration of the procedure, are anticipated to propel the global NIPT market during the forecast period.

According to sources from Down’s Syndrome Education (DSE) International, the prevalence of Down’s syndrome ranges from 1 in 1,500 to 1 in 400 babies born across different countries. Nearly 220,000 babies are born with Down’s syndrome globally every year. According to the CDC, the incidence rate stands at 1 in every 700 childbirths (around 6,000 annually) in the U.S. According to the Centers for Disease Control and Prevention (CDC), every year, around 6,000 babies born in the U.S suffer from Down’s syndrome, which is 1 in every 700 babies.

Increase in Maternal Age to Propel Global Market

Globally, the average age of first-time mothers is increasing, especially in developed countries such as the U.S., the U.K., France, Germany, Italy, and Japan. Financial stability, rising literacy rates, and social factors are responsible for the advancing maternal age. The risk of fetal chromosomal abnormalities is directly related to the rise in maternal age.

According to the American Academy of Family Physicians (AAFP), the risk of fetal chromosomal abnormalities increases progressively up to the age of 30, then rapidly beyond that. According to sources, the chance of Down's syndrome in a newborn is 1/1,300 up to 25 years of maternal age, while the risk increases to 1/365 in pregnant women at 35 years of age and to 1/30 after 40 years. Thus, growth in average maternal age is likely to result in an increase in the incidence of chromosomal abnormalities, leading to a rise in demand for NIPTs.

Request a custom report on Non-invasive Prenatal Testing (NIPT) Market

Strong Brand Reputation Fueling MaterniT21 Segment

In terms of test type, the global market has been classified into Materni21, Harmony, Panorama, Verifi, NIFTY, and others. The MaterniT21 segment accounted for a significant share of the global market in 2021. It is likely to be a highly lucrative segment during the forecast period. The MaterniT21 segment is anticipated to be driven by the strong brand reputation of Labcorp and the expected collaboration with local distributors in the near future.

In September 2019, Labcorp announced the findings of the largest research on cell-free DNA (cfDNA) screenings in multifetal pregnancies to date. The study, published in PLOS ONE (peer-reviewed open access scientific journal), concluded that non-invasive cfDNA screening with Labcorp's Integrated Genetics' MaterniT21 PLUS test delivered trustworthy findings that compared favorably to singleton pregnancies.

High Efficiency of NIPT in Screening of Down’s Syndrome Fueling Trisomy Segment

Based on application, the trisomy segment held a significant share of the global NIPT market in 2021. It is likely to be a highly lucrative segment during the forecast period. According to the United Nations, the estimated rate of incidence of Down’s syndrome ranges from 1 in 1,000 live births per year to 1 in 1,100 live births per year globally. Around 95% of cases of Down’s syndrome are nondisjunction cases, while translocation and mosaicism cases account for 5%.

The dominance of the trisomy segment can be ascribed to the rise in the prevalence of Down’s syndrome globally and the high efficiency of NIPT for screening of Down’s syndrome. Similarly, maternal age is the most important risk factor for trisomy. Women in their late 30s and 40s have a higher chance of having trisomy. Thus, a rise in average maternal age is anticipated to result in an increase in trisomy cases, which is likely to augment the segment.

Significant Popularity in NIPT Driving Next-generation Sequencing (NGS) Segment

In terms of technology, the next-generation sequencing (NGS) segment accounted for the largest global market share in 2021. NGS has gained significant popularity in NIPT. Furthermore, the majority of commercialized NIPT tests are based on next-generation sequencing technology. For instance, MaterniT21 and Harmony are based on the NGS technique.

Improving Diagnostic Laboratory Infrastructure Bolstering Diagnostic Laboratories Segment

Based on end-user, the diagnostic laboratories segment is anticipated to grow at a rapid pace during the forecast period due to improving diagnostic laboratory infrastructure as compared to hospitals. A large number of diagnostic laboratories across the globe offer NIPT. MedGenome Labs Ltd. offers MedGenome Claria NIPT test for the diagnosis of Trisomies 21, 18, and 13; Monosomy X; and other sex chromosomal abnormalities.

The company also offers Claria NIPT Plus, which is used to detect Down Syndrome, Edwards’ Syndrome, Patau Syndrome, Triploidy, Monosomy X (Turner Syndrome), Klinefelter Syndrome, Triple X, Jacob’s Syndrome, 22q11.2 Deletion Syndrome, 1p36 Deletion Syndrome, Prader-Willi Syndrome, Angelman Syndrome, and Cri-du-chat Syndrome.

Regional Outlook of Global Market of Non-invasive Prenatal Testing

North America dominated the global market, with more than 60% share in 2021, followed by Europe. A high rate of diagnosis and treatment of trisomy disorders, well-established healthcare infrastructure, and the presence of key companies in the U.S. are likely to drive the non-invasive prenatal testing market in North America during the forecast period.

The market in Asia Pacific is projected to grow at the fastest CAGR during the forecast period owing to the rise in maternal age, which contributes to the increase in the incidence of chromosomal aneuploidies in babies. Significant market developments in China and Japan, technological integration of NGS procedures, and improving healthcare infrastructure are the other factors propelling the market in the region.

Analysis of Key Players in the Global Non-invasive Prenatal Testing (NIPT) Market

The global market is consolidated due to the broad range of product offerings and strong distribution network of key players in emerging and developed countries. Companies have adopted several strategies, including partnership, merger, acquisition, and product expansion, to strengthen their market position. For instance, in June 2021, Next-Generation Genomic Co., Ltd., and Illumina, Inc. launched VeriSeq NIPT Solution v2 in Thailand.

VeriSeq NIPT Solution offers accurate, reliable, scalable, and fast end-to-end genome-wide noninvasive prenatal testing. Berry Genetics, BGI, Laboratory Corporation of America Holdings, Agilent Technologies, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, Natera, Inc., PerkinElmer, Inc., Eurofins LifeCodexx AG, QIAGEN, Pacific Biosciences, and IGENOMIX are the key players operating in the global non-invasive prenatal testing industry.

Key Developments in Global Non-invasive Prenatal Testing Market

  • In January 2022, QIAGEN collaborated with Atila BioSystems to supply non-invasive prenatal testing (NIPT) solutions to QIAGEN's dPCR business
  • In July 2021, Pacific Biosciences signed a definitive merger agreement to acquire Omniome, a San Diego-based company developing a highly differentiated, proprietary short-read sequencing platform capable of delivering high accuracy. The company chose Omniome due to its novel approach to getting a precise short-read sequencing platform to fast-growing clinical application areas in oncology, transcriptomics, metagenomics, and non-invasive prenatal testing (NIPT).
  • In 2017, Natera, Inc. launched Vistara, a NIPT solution that screens single gene abnormalities across 30 genes. It is an alternative/complement to Panorama and screens for severe skeletal, cardiac, and oncological conditions that are related to cognitive disorders and require surgical interventions.

Each of these players has been profiled in the non-invasive prenatal testing market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Non-invasive Prenatal Testing Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 2.1 Bn

Market Forecast Value in 2031

More than US$ 8.4 Bn

Growth Rate (CAGR) for 2022-2031

14.8%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis at the global as well as regional levels. Moreover, the qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Test Type
    • Materni21
    • Harmony
    • Panorama
    • Verifi
    • NIFTY
    • Others
  • Application
    • Trisomy
    • Micro-deletions Symptoms
    • Others (including sex chromosomes disorders)
  • Technology
    • NGS
    • WGS
    • Others
  • End-user
    • Hospitals
    • Diagnostic Laboratories
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Berry Genetics
  • BGI
  • Laboratory Corporation of America Holdings
  • Agilent Technologies, Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Natera, Inc.
  • PerkinElmer Inc.
  • Eurofins LifeCodexx AG
  • IGENOMIX
  • Pacific Biosciences

Customization Scope

Available upon request

Pricing

Available upon request

Non-invasive Prenatal Testing Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global non-invasive prenatal testing market in 2021?

The global non-invasive prenatal testing industry was valued at US$ 2.1 Bn in 2021

How big will be the global non-invasive prenatal testing (NIPT) market in 2031?

The global market is projected to reach more than US$ 8.4 Bn by 2031

What will be the CAGR of the global NIPT market during the forecast period (2022–2031)?

The global non-invasive prenatal testing market is anticipated to advance at a CAGR of 14.8% from 2022 to 2031

Which are the prominent trends that affect market growth?

High incidence rate of Down’s syndrome

Who are the prominent players in the global non-invasive prenatal testing industry?

Berry Genetics, BGI, Laboratory Corporation of America Holdings, Agilent Technologies, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., Natera, Inc., PerkinElmer, Inc., Eurofins LifeCodexx AG, QIAGEN, Pacific Biosciences, and IGENOMIX

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Non-invasive Prenatal Testing Market

4. Market Overview

    4.1. Introduction

        4.1.1. Test Type Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Non-invasive Prenatal Testing Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Key Industry Evolution/Developments

    5.2. Cost Comparison Analysis

    5.3. Advancement in NIPT

    5.4. Covid 19 Impact Analysis

6. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by Test Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Test Type, 2017–2031

        6.3.1. Materni21

        6.3.2. Harmony

        6.3.3. Panorama

        6.3.4. Verifi

        6.3.5. NIFTY

        6.3.6. Others

    6.4. Market Attractiveness Analysis, by Test Type

7. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by Application

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Application, 2017–2031

        7.3.1. Trisomy

        7.3.2. Micro-deletions Symptoms

        7.3.3. Others

    7.4. Market Attractiveness Analysis, by Application

8. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by Technology

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Technology, 2017–2031

        8.3.1. NGS

        8.3.2. WGS

        8.3.3. Others

    8.4. Market Attractiveness Analysis, by Technology

9. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by End-user

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by End-user, 2017–2031

        9.3.1. Hospitals

        9.3.2. Diagnostic Laboratories

        9.3.3. Others

    9.4. Market Attractiveness Analysis, by End-user

10. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast, by Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Market Attractiveness Analysis, by Region

11. North America Non-invasive Prenatal Testing Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Test Type, 2017–2031

        11.2.1. Materni21

        11.2.2. Harmony

        11.2.3. Panorama

        11.2.4. Verifi

        11.2.5. NIFTY

        11.2.6. Others

    11.3. Market Value Forecast, by Application, 2017–2031

        11.3.1. Trisomy

        11.3.2. Micro-deletions Symptoms

        11.3.3. Others

    11.4. Market Value Forecast, by Technology, 2017–2031

        11.4.1. NGS

        11.4.2. WGS

        11.4.3. Others

    11.5. Market Value Forecast, by End-user, 2017–2031

        11.5.1. Hospitals

        11.5.2. Diagnostic Laboratories

        11.5.3. Others

    11.6. Market Value Forecast, by Country, 2017–2031

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis

        11.7.1. By Test Type

        11.7.2. By Application

        11.7.3. By Technology

        11.7.4. By End-user

        11.7.5. By Country

12. Europe Non-invasive Prenatal Testing Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Test Type, 2017–2031

        12.2.1. Materni21

        12.2.2. Harmony

        12.2.3. Panorama

        12.2.4. Verifi

        12.2.5. NIFTY

        12.2.6. Others

    12.3. Market Value Forecast, by Application, 2017–2031

        12.3.1. Trisomy

        12.3.2. Micro-deletions Symptoms

        12.3.3. Others

    12.4. Market Value Forecast, by Technology, 2017–2031

        12.4.1. NGS

        12.4.2. WGS

        12.4.3. Others

    12.5. Market Value Forecast, by End-user, 2017–2031

        12.5.1. Hospitals

        12.5.2. Diagnostic Laboratories

        12.5.3. Others

    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis

        12.7.1. By Test Type

        12.7.2. By Application

        12.7.3. By Technology

        12.7.4. By End-user

        12.7.5. By Country/Sub-region

13. Asia Pacific Non-invasive Prenatal Testing Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Test Type, 2017–2031

        13.2.1. Materni21

        13.2.2. Harmony

        13.2.3. Panorama

        13.2.4. Verifi

        13.2.5. NIFTY

        13.2.6. Others

    13.3. Market Value Forecast, by Application, 2017–2031

        13.3.1. Trisomy

        13.3.2. Micro-deletions Symptoms

        13.3.3. Others

    13.4. Market Value Forecast, by Technology, 2017–2031

        13.4.1. NGS

        13.4.2. WGS

        13.4.3. Others

    13.5. Market Value Forecast, by End-user, 2017–2031

        13.5.1. Hospitals

        13.5.2. Diagnostic Laboratories

        13.5.3. Others

    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Market Attractiveness Analysis

        13.7.1. By Test Type

        13.7.2. By Application

        13.7.3. By Technology

        13.7.4. By End-user

        13.7.5. By Country/Sub-region

14. Latin America Non-invasive Prenatal Testing Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Test Type, 2017–2031

        14.2.1. Materni21

        14.2.2. Harmony

        14.2.3. Panorama

        14.2.4. Verifi

        14.2.5. NIFTY

        14.2.6. Others

    14.3. Market Value Forecast, by Application, 2017–2031

        14.3.1. Trisomy

        14.3.2. Micro-deletions Symptoms

        14.3.3. Others

    14.4. Market Value Forecast, by Technology, 2017–2031

        14.4.1. NGS

        14.4.2. WGS

        14.4.3. Others

    14.5. Market Value Forecast, by End-user, 2017–2031

        14.5.1. Hospitals

        14.5.2. Diagnostic Laboratories

        14.5.3. Others

    14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis

        14.7.1. By Test Type

        14.7.2. By Application

        14.7.3. By Technology

        14.7.4. By End-user

        14.7.5. By Country/Sub-region

15. Middle East & Africa Non-invasive Prenatal Testing Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Test Type, 2017–2031

        15.2.1. Materni21

        15.2.2. Harmony

        15.2.3. Panorama

        15.2.4. Verifi

        15.2.5. NIFTY

        15.2.6. Others

    15.3. Market Value Forecast, by Application, 2017–2031

        15.3.1. Trisomy

        15.3.2. Micro-deletions Symptoms

        15.3.3. Others

    15.4. Market Value Forecast, by Technology, 2017–2031

        15.4.1. NGS

        15.4.2. WGS

        15.4.3. Others

    15.5. Market Value Forecast, by End-user, 2017–2031

        15.5.1. Hospitals

        15.5.2. Diagnostic Laboratories

        15.5.3. Others

    15.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis

        15.7.1. By Test Type

        15.7.2. By Application

        15.7.3. By Technology

        15.7.4. By End-user

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player - Competition Matrix (by tier and size of companies)

    16.2. Market Share Analysis, by Company, 2021

    16.3. Company Profiles

        16.3.1. Berry Genetics

            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.1.2. Financial Analysis

            16.3.1.3. Growth Strategies

            16.3.1.4. SWOT Analysis

        16.3.2. BGI

            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.2.2. Financial Analysis

            16.3.2.3. Growth Strategies

            16.3.2.4. SWOT Analysis

        16.3.3. Laboratory Corporation of America Holdings

            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.3.2. Financial Analysis

            16.3.3.3. Growth Strategies

            16.3.3.4. SWOT Analysis

        16.3.4. Agilent Technologies, Inc.

            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.4.2. Financial Analysis

            16.3.4.3. Growth Strategies

            16.3.4.4. SWOT Analysis

        16.3.5. Illumina, Inc.

            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.5.2. Financial Analysis

            16.3.5.3. Growth Strategies

            16.3.5.4. SWOT Analysis

        16.3.6. F. Hoffmann-La Roche Ltd.

            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.6.2. Financial Analysis

            16.3.6.3. Growth Strategies

            16.3.6.4. SWOT Analysis

        16.3.7. PerkinElmer, Inc.

            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.7.2. Financial Analysis

            16.3.7.3. Growth Strategies

            16.3.7.4. SWOT Analysis

        16.3.8. Eurofins LifeCodexx AG

            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.8.2. Financial Analysis

            16.3.8.3. Growth Strategies

            16.3.8.4. SWOT Analysis

        16.3.9. QIAGEN

            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.9.2. Financial Analysis

            16.3.9.3. Growth Strategies

            16.3.9.4. SWOT Analysis

        16.3.10. IGENOMIX

            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.10.2. Financial Analysis

            16.3.10.3. Growth Strategies

            16.3.10.4. SWOT Analysis

        16.3.11. Pacific Biosciences

            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.11.2. Financial Analysis

            16.3.11.3. Growth Strategies

            16.3.11.4. SWOT Analysis

        16.3.12. Natera, Inc.

            16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.12.2. Financial Analysis

            16.3.12.3. Growth Strategies

            16.3.12.4. SWOT Analysis

List of Tables

Table 01: Global Non-invasive Prenatal Testing Market Value Share, by Test Type, 2021

Table 02: Global Non-invasive Prenatal Testing Market Value Share, by Application, 2021

Table 03: Global Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 04: Global Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 05: Global Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031

Table 06: Global Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 07: Global Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 08: North America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 09: North America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 10: North America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031

Table 11: North America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 12: North America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 13: Europe Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 14: Europe Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 15: Europe Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031

Table 16: Europe Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 17: Europe Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Asia Pacific Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 19: Asia Pacific Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 20: Asia Pacific Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031

Table 21: Asia Pacific Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 22: Asia Pacific Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 23: Latin America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 24: Latin America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 25: Latin America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031

Table 26: Latin America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 27: Latin America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 28: Middle East & Africa Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 29: Middle East & Africa Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 30: Middle East & Africa Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031

Table 31: Middle East & Africa Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 32: Middle East & Africa Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

List of Figures

Figure 01: Global Non-invasive Prenatal Testing Market Snapshot

Figure 02: Global Non-invasive Prenatal Testing Market Segments With Leading Market Share (%), 2021

Figure 03: Key Industry Developments (Non-invasive Prenatal Testing Market)

Figure 04: Global Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, 2017‒2031

Figure 05: Global Non-invasive Prenatal Testing Market Value Share (%), by Test Type (2021)

Figure 06: Global Non-invasive Prenatal Testing Market Value Share (%), by Application (2021)

Figure 07: Global Non-invasive Prenatal Testing Market Value Share (%), by Technology (2021)

Figure 08: Global Non-invasive Prenatal Testing Market Value Share(%), by End-user (2021)

Figure 09: Global Non-invasive Prenatal Testing Market Value Share (%), by Region (2021)

Figure 10: Global Non-invasive Prenatal Testing Market Value Share Analysis, by Test Type, 2021 and 2031

Figure 11: Global Non-invasive Prenatal Testing Market Attractiveness Analysis, by Test Type, 2022–2031

Figure 12: Global Non-invasive Prenatal Testing Market Value Share Analysis, by Application, 2021 and 2031

Figure 13: Global Non-invasive Prenatal Testing Market Attractiveness Analysis, by Application, 2022–2031

Figure 14: Global Non-invasive Prenatal Testing Market Value Share Analysis, by Technology, 2021 and 2031

Figure 15: Global Non-invasive Prenatal Testing Market Attractiveness Analysis, by Technology, 2022–2031

Figure 16: Global Non-invasive Prenatal Testing Market Value Share(%), by End-user, 2021 and 2031

Figure 17: Global Non-invasive Prenatal Testing Market Attractiveness Analysis, by End-user, 2022–2031

Figure 18: Global Non-invasive Prenatal Testing Market Value Share Analysis, by Region 2021 and 2031

Figure 19: Global Non-invasive Prenatal Testing Market Attractiveness Analysis, by Region, 2022–2031

Figure 20: North America Non-invasive Prenatal Testing Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031

Figure 21: North America Non-invasive Prenatal Testing Market Value Share (%), by Test Type, 2021 and 2031

Figure 22: North America Non-invasive Prenatal Testing Market Attractiveness Analysis, by Test Type, 2022–2031

Figure 23: North America Non-invasive Prenatal Testing Market Value Share (%), by Application, 2021 and 2031

Figure 24: North America Non-invasive Prenatal Testing Market Attractiveness Analysis, by Application, 2022–2031

Figure 25: North America Non-invasive Prenatal Testing Market Value Share (%), by Technology, 2021 and 2031

Figure 26: North America Non-invasive Prenatal Testing Market Attractiveness Analysis, by Technology, 2022–2031

Figure 27: North America Non-invasive Prenatal Testing Market Share (%), by End-user, 2021 and 2031

Figure 28: North America Non-invasive Prenatal Testing Market Attractiveness Analysis, by End-user, 2022–2031

Figure 29: North America Non-invasive Prenatal Testing Market Value Share (%), by Country, 2021 and 2031

Figure 30: North America Non-invasive Prenatal Testing Market Attractiveness Analysis, by Country, 2022–2031

Figure 31: Europe Non-invasive Prenatal Testing Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031

Figure 32: Europe Non-invasive Prenatal Testing Market Value Share (%), by Test Type, 2021 and 2031

Figure 33: Europe Non-invasive Prenatal Testing Market Attractiveness Analysis, by Test Type, 2022–2031

Figure 34: Europe Non-invasive Prenatal Testing Market Value Share (%), by Application, 2021 and 2031

Figure 35: Europe Non-invasive Prenatal Testing Market Attractiveness Analysis, by Application, 2022–2031

Figure 36: Europe Non-invasive Prenatal Testing Market Value Share (%), by Technology, 2021 and 2031

Figure 37: Europe Non-invasive Prenatal Testing Market Attractiveness Analysis, by Technology, 2022–2031

Figure 38: Europe Non-invasive Prenatal Testing Market Share (%), by End-user, 2021 and 2031

Figure 39: Europe Non-invasive Prenatal Testing Market Attractiveness Analysis, by End-user, 2022–2031

Figure 40: Europe Non-invasive Prenatal Testing Market Value Share (%), by Country/Sub-region, 2021 and 2031

Figure 41: Europe Non-invasive Prenatal Testing Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 42: Asia Pacific Non-invasive Prenatal Testing Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031

Figure 43: Asia Pacific Non-invasive Prenatal Testing Market Value Share (%), by Test Type, 2021 and 2031

Figure 44: Asia Pacific Non-invasive Prenatal Testing Market Attractiveness Analysis, by Test Type, 2022–2031

Figure 45: Asia Pacific Non-invasive Prenatal Testing Market Value Share (%), by Application, 2021 and 2031

Figure 46: Asia Pacific Non-invasive Prenatal Testing Market Attractiveness Analysis, by Application, 2022–2031

Figure 47: Asia Pacific Non-invasive Prenatal Testing Market Value Share (%), by Technology, 2021 and 2031

Figure 48: Asia Pacific Non-invasive Prenatal Testing Market Attractiveness Analysis, by Technology, 2022–2031

Figure 49: Asia Pacific Non-invasive Prenatal Testing Market Share (%), by End-user, 2021 and 2031

Figure 50: Asia Pacific Non-invasive Prenatal Testing Market Attractiveness Analysis, by End-user, 2022–2031

Figure 51: Asia Pacific Non-invasive Prenatal Testing Market Attractiveness Analysis, by End-user, 2021 and 2031

Figure 52: Asia Pacific Non-invasive Prenatal Testing Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 53: Latin America Non-invasive Prenatal Testing Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031

Figure 54: Latin America Non-invasive Prenatal Testing Market Value Share (%), by Test Type, 2021 and 2031

Figure 55: Latin America Non-invasive Prenatal Testing Market Attractiveness Analysis, by Test Type, 2022–2031

Figure 56: Latin America Non-invasive Prenatal Testing Market Value Share (%), by Application, 2021 and 2031

Figure 57: Latin America Non-invasive Prenatal Testing Market Attractiveness Analysis, by Application, 2022–2031

Figure 58: Latin America Non-invasive Prenatal Testing Market Value Share (%), by Technology, 2021 and 2031

Figure 59: Latin America Non-invasive Prenatal Testing Market Attractiveness Analysis, by Technology, 2022–2031

Figure 60: Latin America Non-invasive Prenatal Testing Market Share (%), by End-user, 2021 and 2031

Figure 61: Latin America Non-invasive Prenatal Testing Market Attractiveness Analysis, by End-user, 2022–2031

Figure 62: Latin America Non-invasive Prenatal Testing Market Value Share (%), by Country/Sub-region, 2021 and 2031

Figure 63: Latin America Non-invasive Prenatal Testing Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 64: Middle East & Africa Non-invasive Prenatal Testing Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031

Figure 65: Middle East & Africa Non-invasive Prenatal Testing Market Value Share (%), by Test Type, 2021 and 2031

Figure 66: Middle East & Africa Non-invasive Prenatal Testing Market Attractiveness Analysis, by Test Type, 2022–2031

Figure 67: Middle East & Africa Non-invasive Prenatal Testing Market Value Share (%), by Application, 2021 and 2031

Figure 68: Middle East & Africa Non-invasive Prenatal Testing Market Attractiveness Analysis, by Application, 2022–2031

Figure 69: Middle East & Africa Non-invasive Prenatal Testing Market Value Share (%), by Technology, 2021 and 2031

Figure 70: Middle East & Africa Non-invasive Prenatal Testing Market Attractiveness Analysis, by Technology, 2022–2031

Figure 71: Middle East & Africa Non-invasive Prenatal Testing Market Share (%), by End-user, 2021 and 2031

Figure 72: Middle East & Africa Non-invasive Prenatal Testing Market Attractiveness Analysis, by End-user, 2022–2031

Figure 73: Middle East & Africa Non-invasive Prenatal Testing Market Value Share (%), by Country/Sub-region, 2021 and 2031

Figure 74: Middle East & Africa Non-invasive Prenatal Testing Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

896

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved